BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Schrödinger: The Cost Machine That Learned to Cost Less

Moe Alsumidaie by Moe Alsumidaie
November 17, 2026
in Research Notes
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Schrödinger spent three decades building physics simulations so precise that major pharmaceutical companies use them to design drugs before synthesizing a single molecule. It went public in February 2020 riding that reputation, and for a while the market priced it like a software company with a drug pipeline attached. Then the losses mounted, the pipeline consumed cash, and the stock fell from the mid-thirties to under eleven dollars by March 2026. What happened next is the story worth reading.

First, the shape of it

The filed numbers show a company that is spending less to earn more: Q3 2026 operating expenses fell 13% year-over-year while revenue rose 19%, a combination that rarely appears in the same quarter for a company still running losses. The stock has more than doubled since January, pricing in a version of Schrödinger that does not yet exist in the filings. The open question is whether the cost discipline is structural or a one-quarter coincidence, and the answer is not yet in the data.

A year of two Schrödinger companies

The 10-K for fiscal year 2025 shows revenue of $256 million, up nearly a quarter from the prior year, with a net loss equal to roughly 40 cents of every dollar earned. That loss ratio sounds alarming until you compare it to fiscal 2024, when the company lost nearly ninety cents on every dollar of revenue. Something changed between those two filings, and the Q3 2026 report shows the change accelerating.

The mechanism is simpler than it sounds. Schrödinger runs two businesses inside one company: a software platform that pharmaceutical and materials-science firms license to simulate molecular behavior, and an internal drug discovery operation that bets Schrödinger’s own money on promising compounds. The drug side is expensive and lumpy, paying out in milestone checks when a partner hits a clinical target rather than in steady monthly fees. When the drug side had a bad year, the whole company looked like it was burning down. When it has a good quarter, the numbers jump in ways that can mislead.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: SDGR and 500+ other names, on the same official data.See the evidence engine →

What the Q3 filing actually says

The Q3 2026 press release filed November 4, 2026 shows total revenue of $64.5 million for the quarter. A large portion of drug discovery revenue within that figure was a milestone payment from Structure Therapeutics, a company Schrödinger co-founded, for an obesity drug candidate. Milestone payments are real money, but they are not subscriptions. The distinction between milestone payments and recurring subscription revenue is material to any assessment of revenue quality.

The more durable signal is on the cost side. R&D expenses dropped from roughly four-fifths of revenue in Q3 2025 to just over half in Q3 2026, according to our data computed from the filed figures. That is not a rounding error. Schrödinger has trimmed headcount and, more significantly, has stopped running internal clinical trials, handing that expensive work to partners. The company has stated a target of positive cash earnings by end of 2028. The cash cushion as of September 30, 2026 stood at $373 million, which at recent quarterly burn rates represents meaningful runway to reach that target.

The portfolio bets hiding in the balance sheet

Schrödinger does not just license software and run its own labs. It takes equity stakes in the biotechs it helps found, and those stakes move with the market. In April 2026, Eli Lilly announced a multibillion-dollar acquisition of Ajax Therapeutics, in which Schrödinger holds a meaningful equity stake. That is a significant windfall relative to the company’s annual revenue. Conversely, the Q3 net loss was wider than the same quarter a year earlier, not because operations deteriorated, but because mark-to-market changes in public equity positions added a substantial accounting charge. The operating story and the accounting story are running in opposite directions, which makes the headline loss number a poor guide to what is actually happening in the business.

In September 2026, Schrödinger co-founded Tectora Therapeutics with NEA and RA Capital, contributing two early-stage programs for equity and future milestones after Tectora’s $55 million Series A financing. The pattern is consistent: Schrödinger seeds a company, retains upside, and offloads the clinical cost. Whether that model produces durable value depends on the quality of the science, which no filing can fully answer.

The mood the market is paying for

“The math” is what filed fundamentals justify; “the mood” is what the market is currently paying. The stock opened 2026 near fourteen dollars and trades close to double that today, a near-doubling in under a year. Our data shows the price-to-sales multiple sitting near the decade median, which suggests the mood is not yet at the extreme end of historical enthusiasm. The price-to-earnings multiple is a different story: at a level that sits at the 99th percentile of Schrödinger’s own history, it reflects a single profitable year in 2023 that the market is treating as a permanent condition. The 2024 and 2025 filings show it was not.

Bank of America, BMO Capital, and TD Cowen each maintained positive ratings after the Q3 report, with TD Cowen revising its valuation reference point upward to $36; UBS and Morgan Stanley held neutral stances. These reflect a range of external analytical views as of the filing date. The honest summary from the filings: the cost structure is genuinely improving, the software platform is growing at a healthy clip by contract value, and the drug portfolio is producing real milestones. The honest caveat: the stock has already priced in a great deal of that improvement, and the path to sustained profitability runs through 2028 on management’s own timeline.

Reading the numbers

  • $373 million in cash and securities (September 30, 2026): This is the company’s financial cushion, the money available before it needs to raise more. Think of it as roughly eighteen months of operating expenses at the current run rate. It is the number that determines whether Schrödinger reaches its 2028 profitability target without diluting existing shareholders.
  • 17% ACV growth: Annual Contract Value measures the recurring software subscription base, the steady-fee part of the business. Growing 17% means that for every $100 of software contracts Schrödinger held a year ago, it now holds about $117. That is the engine; the drug milestones are the bonus.
  • R&D expenses at 53% of revenue vs. 79% a year ago: Imagine a restaurant that spent 79 cents of every dollar of sales on ingredients and kitchen staff last year and now spends 53 cents. The food is the same; the kitchen got leaner. That gap, if it holds, is what eventually turns a loss into a profit.
  • Net loss of $37.7 million in Q3 2026: The headline number looks worse than Q3 2025. But $11.4 million of that loss came from accounting rules that require Schrödinger to mark its equity stakes in public companies to market each quarter, a paper charge that reverses when those stocks rise. Strip it out and the operating loss narrowed meaningfully.

Sources

  • 10-Q for quarter ended September 30, 2026 (SEC EDGAR)
  • 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
  • 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
  • Schrödinger Q3 2026 earnings press release
  • MLQ.ai: Schrödinger raises 2026 outlook
  • Tectora Therapeutics licensing announcement
  • MarketBeat: TD Cowen raises target to $36
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read SDGR’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

LifeVantage: A $58 Million Buyback Program and a Quarter That Lost Money

by Moe Alsumidaie
November 20, 2026
0

LifeVantage spent most of the last decade building its reputation on a single idea: that a supplement called Protandim could slow the cellular wear-and-tear that comes with aging....

Read moreDetails

AnaptysBio: The Royalty Company That Used to Be a Drug Company

by Moe Alsumidaie
November 19, 2026
0

For most of its life, AnaptysBio was a bet on science. It discovered drug candidates, ran trials, and hoped one would survive long enough to reach patients. Then,...

Read moreDetails

Vafseo Is Growing. Auryxia Is Collapsing. Both Are True at Once.

by Moe Alsumidaie
November 19, 2026
0

Four years ago, Akebia Therapeutics was a company the FDA had just rejected, laying off nearly half its staff and watching its lead partner walk away. Today, that...

Read moreDetails

Vaxart: Government Revenue Falls 85%, and the Clock Starts Ticking

by Moe Alsumidaie
November 19, 2026
0

A year ago, Vaxart looked like a company with a government backstop. BARDA, the federal agency that funds pandemic preparedness, had committed hundreds of millions of dollars to...

Read moreDetails

Keros Therapeutics: A Quarter That Earned Its Keep, and the Longer Bet Behind It

by Moe Alsumidaie
November 18, 2026
0

Eighteen months ago, Keros cut nearly half its staff and buried its most advanced drug. Today, the same company is posting net income, sitting on a cash pile...

Read moreDetails
Next Post

Evidence Sheet: Schrodinger (SDGR)

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Evidence Sheet: Palantir Technologies (PLTR)

November 6, 2026

One Drug, Nearly a Billion Dollars, and a Pipeline That Just Blinked

October 21, 2026

Zoetis: The Margin Holds, the Stock Does Not

October 12, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.